Prelude Therapeutics Gestion
Gestion contrôle des critères 4/4
Le PDG Prelude Therapeutics est Kris Vaddi, nommé en Feb2016, a un mandat de 10.25 ans. La rémunération annuelle totale est $ 1.35M, composée du salaire de 45.7% et des bonus 54.3%, y compris les actions et options de la société. détient directement 3.1% des actions de la société, d'une valeur de $ 13.31M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.4 ans et 6 ans.
Informations clés
Kris Vaddi
Directeur général
US$1.3m
Rémunération totale
| Pourcentage du salaire du PDG | 45.66% |
| Durée du mandat du directeur général | 10.3yrs |
| Propriété du PDG | 3.1% |
| Durée moyenne d'occupation des postes de direction | 4.4yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 6yrs |
Mises à jour récentes de la gestion
Recent updates
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Shareholders might have noticed that Prelude Therapeutics Incorporated ( NASDAQ:PRLD ) filed its first-quarter result...
Future Returns Will Depend On JAK2 Program Validation And Incyte Milestones
Catalysts About Prelude Therapeutics Prelude Therapeutics is a clinical stage oncology company focused on discovering and developing precision cancer medicines. What are the underlying business or industry changes driving this perspective?Prelude Therapeutics Incorporated's (NASDAQ:PRLD) 66% Share Price Plunge Could Signal Some Risk
Prelude Therapeutics Incorporated ( NASDAQ:PRLD ) shares have retraced a considerable 66% in the last month, reversing...Prelude Therapeutics: A Subtle Shift In Pipeline Underscores Funding Challenges
Summary Prelude Therapeutics continues to explore the SMARCA2 anticancer approach, with no major hiccups disclosed to date. A strategic shift from their main pipeline contender raises concerns about data not yet disclosed, however. PRLD's funding situation is also in doubt, as they will find themselves needing to raise cash in the coming months. An upcoming ASH presentation could also shed some light on the next steps for two preclinical projects in myeloproliferative neoplasms. Read the full article on Seeking AlphaPrelude Therapeutics (NASDAQ:PRLD) Will Have To Spend Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data
Summary Prelude Therapeutics once produced positive clinical data from a now abandoned program. The company's current lead candidates are PRT3789, a SMARCA2 inhibitor, and PRT2527, a CDK9 inhibitor, both in phase 1 trials. Both programs have early preclinical data and look scientifically interesting. However, they are too early to merit an investment right now, although they bear watching. Read the full article on Seeking AlphaHere's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...Prelude wins FDA clearance to start Phase 1 trial for cancer candidate
Prelude Therapeutics (NASDAQ:PRLD), an oncology-focused biotech, announced Tuesday that the FDA cleared its Investigational New Drug Application (IND) for PRT3789 allowing the company to start a Phase 1 trial for the antitumor agent. A protein degrader targeted at SMARCA2 (BRM) mutations in cancer tissue, PRT3789, has demonstrated antitumor activity in preclinical models at well-tolerated doses, the company said. “Clearance of the IND for PRT3789 represents a major milestone for Prelude Therapeutics, as we advance our first-in-class SMARCA2 protein degrader from discovery to the clinic,” Dr. Peggy Scherle, Chief Scientific Officer of Prelude (PRLD), noted. The Phase 1 trial for PRT3789 is designed to enroll patients with advanced solid tumors harboring SMARCA4. The dosing is expected to start in Q1 2023. PRLD awaits multiple catalysts in its clinical programs this year.Prelude downgraded at Morgan Stanley ahead of key update
Prelude Therapeutics (NASDAQ:PRLD) inched lower on Friday after Morgan Stanley downgraded the cancer-focused biotech to Equal Weight from Overweight as the company plans to disclose key steps forward for its PRMT5 program, including the solid tumor candidate PRT811 in H2 2022. The analysts see upside potential as PRLD remains on track to report early findings from its MCL1 inhibitor program and CDK9 inhibitor program during the second half of 2022. However, they see better opportunities elsewhere in the coverage noting uncertainty over the path forward for PRT811. Morgan Stanley lowers the probability of success for PRT811 in GBM, solid tumors, and myeloid malignancies to 20% from 25%, in line with the range it usually uses for Phase 1 assets, and trims the price target for PRLD to $11 from $19. Early this year, PRLD decided to drop the development of the PRT543 candidate in its PRMT5 program and focus its efforts on PRT811.We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$78m |
| Dec 31 2025 | US$1m | US$615k | -US$99m |
| Sep 30 2025 | n/a | n/a | -US$112m |
| Jun 30 2025 | n/a | n/a | -US$124m |
| Mar 31 2025 | n/a | n/a | -US$128m |
| Dec 31 2024 | US$2m | US$594k | -US$127m |
| Sep 30 2024 | n/a | n/a | -US$132m |
| Jun 30 2024 | n/a | n/a | -US$130m |
| Mar 31 2024 | n/a | n/a | -US$126m |
| Dec 31 2023 | US$3m | US$573k | -US$122m |
| Sep 30 2023 | n/a | n/a | -US$117m |
| Jun 30 2023 | n/a | n/a | -US$117m |
| Mar 31 2023 | n/a | n/a | -US$114m |
| Dec 31 2022 | US$3m | US$558k | -US$115m |
| Sep 30 2022 | n/a | n/a | -US$120m |
| Jun 30 2022 | n/a | n/a | -US$120m |
| Mar 31 2022 | n/a | n/a | -US$120m |
| Dec 31 2021 | US$7m | US$544k | -US$112m |
| Sep 30 2021 | n/a | n/a | -US$98m |
| Jun 30 2021 | n/a | n/a | -US$84m |
| Mar 31 2021 | n/a | n/a | -US$69m |
| Dec 31 2020 | US$12m | US$417k | -US$57m |
| Sep 30 2020 | n/a | n/a | -US$48m |
| Jun 30 2020 | n/a | n/a | -US$38m |
| Mar 31 2020 | n/a | n/a | -US$32m |
| Dec 31 2019 | US$2m | US$315k | -US$28m |
Rémunération vs marché: La rémunération totale de Kris ($USD 1.35M ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 2.64M ).
Rémunération et revenus: La rémunération de Kris a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Kris Vaddi (59 yo)
Dr. Krishna Vaddi, D.V.M., Ph D., also known as Kris, founded Prelude Therapeutics Incorporated and serves as its Chief Executive Officer and Director from February 2016. He has been its Chief Executive Of...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Founder | 10.3yrs | US$1.35m | 3.1% $ 13.3m | |
| CFO, Chief Legal Officer & Corporate Secretary | 3.3yrs | US$847.40k | 0.027% $ 117.0k | |
| Chief Scientific Officer | 8.1yrs | US$819.73k | 0.18% $ 792.9k | |
| Senior VP and Head of Strategic Planning & Operations | 4.3yrs | pas de données | pas de données | |
| Senior Vice President of Technical Operations | 5.3yrs | pas de données | pas de données | |
| Senior Vice President of Investor Relations | 1.3yrs | pas de données | pas de données | |
| Chief People Officer | 4.9yrs | pas de données | pas de données | |
| Executive VP & Chief Chemistry Officer | 7.1yrs | US$2.63m | 0.48% $ 2.1m | |
| Senior Vice President of Translation Medicine | 4.4yrs | pas de données | pas de données | |
| Senior Vice President of Clinical Development | 3.6yrs | pas de données | pas de données | |
| Senior Vice President of Clinical Pharmacology | 1.3yrs | pas de données | pas de données | |
| Chief Business Officer | 2.1yrs | pas de données | 0.099% $ 427.0k |
Gestion expérimentée: L'équipe de direction de PRLD est considérée comme expérimentée (ancienneté moyenne 4.4 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Founder | 10.3yrs | US$1.35m | 3.1% $ 13.3m | |
| Independent Chairman of the Board | 9.8yrs | US$102.53k | 0.50% $ 2.1m | |
| Independent Director | 4.8yrs | US$78.53k | 0% $ 0 | |
| Independent Director | 9.9yrs | US$86.03k | 0% $ 0 | |
| Independent Directors | less than a year | US$77.56k | pas de données | |
| Independent Director | 6yrs | US$194.53k | 0% $ 0 | |
| Independent Directors | less than a year | US$81.57k | pas de données |
Conseil d'administration expérimenté: Les membres du conseil d'administration de PRLD sont considérés comme expérimentés (ancienneté moyenne 6 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/24 00:57 |
| Cours de l'action en fin de journée | 2026/05/22 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Prelude Therapeutics Incorporated est couverte par 6 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Reni Benjamin | Citizens JMP Securities, LLC |
| Jason Kolbert | D. Boral Capital LLC. |